Neuroblastoma: Complete objective response to biological treatment
Complete objective response of neuroblastoma to biological treatment (full PDF)
Abstract
OBJECTIVES: The combined use (DBM) of Somatostatin, Melatonin, Retinoids, Vitamins E, C, and D3, with Calcium, Chondroitin sulfate, and microdoses of Cyclophosphamide in a seven-month old baby affected by a voluminous retroperitoneal neuroblastoma measuring 4×8 cm produced a 50% objective response in six months, an almost total response in one year and a complete response at 14 months, with cure and absence of disease for over ten years.
RESULTS: This paper discusses the rationale and the molecular mechanisms of action of the treatment which has a differentiating, apoptotic and antiproliferative effect, preserving and enhancing both the trophism and functionality of organs and tissues, and the neuroimmunoendocrine and antiblastic homeostasis. This result is in agreement with the positive results already published on the use of the MDB in lymphoproliferative diseases, in stage III and IV lung cancer, in breast cancer and in cancers of the upper aerodigestive epithelia. Without the need for hospitalisation and with no toxicity, the MDB rapidly reduced and then eliminated the voluminous tumoral mass, allowing a normal quality of life and a perfectly normal psychophysical development.
CONCLUSIONS: We believe it is of use to report this case in order to invite greater interest in the oncological possibilities offered by the immunoneuroendocrine and biological-receptorial properties of the DBM treatment.
The purpose of the work was to evaluate the importance of the cytokines, IL-6, IL-8, and TNF-α, and the adhesive molecule, sICAM-1, as risk factors for early-onset neonatal sepsis and intra-amniotic infections.
INTRODUCTION
We present a case of complete remission with biological therapy (DBM) of an unoperable voluminous retroperitoneal neuroblastoma (NBL) in a seven-month old baby. The case has been monitored since 1998. We report the components of the biological therapy (DBM), together with the results of the blood tests and instrumental examinations performed before and after the treatment.
A brief summary is provided of the rationale of the DBM, the scientific bases, the molecular mechanisms of action and the clinical response, with the patient in complete remission for over 10 years!
BRIEF NOTES ON NEUROBLASTOMA
NBL originates from cells of the neural crest, affecting the nerve cells of the sympathetic ganglia and is considered to be hereditary.
It is the most common solid extracranial tumour in children, representing 6–10% of all tumours in infancy with an incidence of 7–13 new cases annually/1,000,000 (children < 15 years).
Neuroblastoma has an extremely variable clinical presentation and biological behaviour. The risk evaluation system drawn up by the COG (Children’s Oncology Group) considers not only histological and histochemical data but also the age of the patient, the volume of the tumour mass and the stage according to INSS criteria (International Neuroblastoma Staging System):
International Neuroblastoma Staging System
INSS - International Neuroblastoma Staging System - combines certain features of the previously used POG and CCG systems [1] [2] and has identified distinct prognostic groups [1] [2] [3].
| Stage 1 | Unilateral or midline tumour confined to the area of origin, removed completely with negative or metastatic lymph nodes removed together with the tumour. |
| Stage 2A | Unilateral or midline tumour, mostly removed but not radically and with negative lymph nodes. |
| Stage 2B | Unilateral or midline tumour, radically removed but with positive lymph nodes. |
| Stage 3 |
Tumour crossing the midline, infiltrating the surrounding tissues ± regional lymph nodes; Tumour that does not cross the midline but with positive contralateral lymph node involvement; Midline tumour which cannot be removed with a sufficiently wide margin due to infiltration of the surrounding tissues. |
| Stage 4 | Dissemination of the tumour to distant lymph nodes, skeleton, bone marrow, liver, skin and/or other organs. |
| Stage 4S | Localised tumour as for Stages 1 and 2, with dissemination limited to the skin, liver and/or bone marrow (less than 10% infiltration) at age less than 1 year old [4]. |
NBL is a highly aggressive tumour, with a few exceptions regarding cases which fall within stage 4S of the INSS classification, in which a progressive differentiation up to spontaneous remission may occur. Except for the rare INSS stage 4 cases, a neuroblastoma generally tends, as in the case presented here, to infiltrate the adjacent structures and organs, rapidly spreading to the nearby lymph nodes. As in this case, a single irregular mass with undefined borders is found at diagnosis, consisting of the primary mass and metastatic lymph nodes.
Neuroblastoma often produces catecholamines (this is why it is called a secreting tumour), causing high levels in the urine and blood, useful for diagnosis and monitoring.
In several cases, hypertension and tachycardia occur, although not always together with the increase in catecholamines and the other catabolites of the sympathetic system.
Neuroblastoma can affect the adrenal gland (presenting as an abdominal tumour) or the paraspinal sympathetic ganglia, and can also appear in any part of the vertebral column (abdominal and thoracic). Frequent signs of the disease include fever, anemia, loss of appetite, and bruising around the eyes. Metastases, which are frequent and appear early, affect the bones, the orbital region, the lymph nodes, the liver and bone marrow. Early diagnosis is fundamental as surgical intervention in the early stages increases survival; it is therefore necessary to test for the urinary metabolites of catecholamine (vanillylmandelic acid, homovanillic acid) and neuroendocrine markers (NSE). Ferritin and lactate dehydrogenase (LDH) are also parameters which should be evaluated when NBL is suspected.
The extent of the disease should be assessed with imaging procedures: CT, MRI, PET, and urography. In most cases, neuroblastoma presents with metastases when diagnosed. Cytogenetic analyses in neuroblastoma show a series of breakpoints of chromosome 1p from 1 P22 to 1 P 36. Chromosome 1 P allele deletions and loss are present not only in NBL, but in a wide range of solid and hematological tumours. The distal region of the short arm of chromosome 1 contains one or more genes implicated in the development of tumours.
CLINICAL CASE
Neuroblastoma (classification: T4-N2-Mx): INSS stage 3
Patient details: Year of birth: 1998 – Sex: M
CASE HISTORY: Born in May 1998 with normal delivery, the child began to suffer continuous problems with his digestive system in November of the same year. As these problems gradually became worse, he was admitted to Hospital in Avola, in Sicily, where ultrasound and CT scans, performed on 17/12/98, revealed a voluminous solid tumour in the left mid-lateral retroperitoneal area (4×8 cm) classified as a NBL. According to NBL classification criteria (International Neuroblastoma Staging System) the case in question was clearly stage 3 (unoperable tumours infiltrating the midline with or without regional lymph node involvement).
INITIAL ROUTINE TESTS
17/Dec/1998: Abdominal CT – Report: "CT of the upper and lower abdomen, performed in basal conditions, revealed the presence of a large solid formation in the left mid-lateral retroperitoneal area with a maximum width of around 4 cm and a maximum length of around 8 cm. The structure of this formation is not uniform, and presents numerous calcifications; it has displaced the intestinal loops forward and the aorta towards the right, and is in close contact with the front margin of the spine. The CT appearance of this formation is compatible with neuroblastoma...".
After the CT scan, the child was transferred to the Gaslini Children’s Hospital in Genoa (Scientific Research and Care Institute), where MRI of the upper and lower abdomen and urography under general anesthesia were carried out on 24/Dec/98.
24/Dec/1998: MRI – Report: "No secondary lesions evident in the liver. No lymphoadenomegaly close to the aorta or vena cava. Normal kidneys and spleen. Confirmed presence of a large expansive process, extending caudally from the renal vascular pedicle to beyond the aorta-iliac division. The mass is midline, extending mainly towards the left (crossing the midline), with displacement of the homolateral psoas. The structure is solid without evidence of necrotic-colliquative phenomena. The signal is clearly hyper-intense in T2 with a hypo-intense diffuse punctiform appearance due to the presence of calcifications. The distal aorta and vena cava, the bifurcation and the iliac veins and arteries (more to the left) are marginally incorporated and displaced towards the right. No liquid in the peritoneum." (Figure 1, Figure 2, Figure 3, Figure 4 and, together, Figure 1-2, Figure 3-4 and Figure 1-2-3-4).
28/Dec/1998: Urography – Report: "Prompt elimination and regular concentration of the iodate contrast medium by both renal excretors. On the right, regular calyx-pyelic and ureteral morphology. On the left, normal calyx-pyelic morphology; the ureter presents a normal calibre but an altered course: in the anterior-posterior projection the proximal tract appears to be outwardly displaced, while in the latero-lateral projection the intermediate tract appears to be pushed forward, probably displaced by the retroperitoneal mass." (Figure 5).
The diagnosis of neuroblastoma made at the hospital in Sicily was confirmed at the Gaslini Institute.
The parents were informed of the unacceptable risk of surgery, not only because of the child’s age but also due to the volume and the marked vascularisation of the tumoral mass, and above all for the difficulty in identifying cleavage planes with the distal aorta and the vena cava, the bifurcation and the iliac veins and arteries, all incorporated by the tumoral mass and displaced towards the left.
The particularly significant volume of the abdominal-pelvic tumour (8 cm. × 4 cm. in a 7-month-old baby) with displacement of the ureter and compression of the intestinal loops was causing gastrointestinal problems, colic and vomiting. Chemotherapy was proposed. An urgent solution was necessary due to the persistence of the gastrointestinal symptoms, the deterioration of the child’s condition and the rapid progression of the tumour. The parents refused chemotherapy and, in January 1999, the child was therefore discharged from the Gaslini hospital with a report to the Pediatric Clinic in Catania, specifying that: "...the suspicion of Neuroblastoma was confirmed by the tests relative to the urinary excretion of sympathetic amines..." (Figure Hem-Chem-Val).
RESULTS
Therapy and clinical course
The parents decided to refuse chemotherapy and to try the DBM.
The treatment prescribed by Prof. Luigi Di Bella and started immediately after the child was discharged from hospital is described below:
-
Solution of:
- All-trans retinoic acid 0.5 g
- Palmitate axerophthol 0.5 g
- Beta carotene 2 g
- Alpha-tocopherol 1000 g
One 2 ml teaspoonful of Solution every 3 hours together with:
- Dihydrotachysterol: one drop in the teaspoon for each administration;
-
Bromocriptine 2.5 mg tablets: 1/4 of a tablet twice a day, morning and evening;
-
Melatonin 12%, Adenosine 51%, Glycine 37%: one 5 mg vial diluted in water;
-
Chondroitin sulfate: one 500 mg vial orally with the evening feed/meal;
-
Cyclophosphamide 50 mg tablets: 1/4 of a tablet with the main feed/meal;
-
Somatostatin – 14 amino acids: one 0.25 mg vial injected slowly subcutaneously in the evening.
The treatment was tolerated and blood tests were scheduled every 2 weeks.
The general conditions of the child improved, with a gradual reduction of the colic attacks, the diarrhea, vomiting and anorexia, and an increase in weight. By the end of 1999, the child’s weight, height and psychophysical development were within the physiological range. The gradual remission of the symptoms was accompanied by a progressive return to normal of the hematochemical values, with a reduction of the leukocytes, ESR, LDH, Ferritin, catecholamines, NSE, vanillylmandelic acid and homovanillic acid. For the first few months, hemochrome was tested every 2 weeks. Complete hematochemical tests were carried out every 2–3 months since, in addition to a high diagnostic value, these are also useful for monitoring remission and to detect recurrences at an early stage, before any clinical signs become evident. The improvement of the hematochemical values was accompanied by a marked and continuous reduction in volume of the tumoral mass detected by imaging procedures. Forty days after starting the MDB, an abdominal ultrasound scan on 12/Feb/1999 showed a reduction of the tumour, reporting: " [...] In the left ilio-pelvic area, close to the vertebral plane, a slightly irregular, egg-shaped neoformation with fairly well-defined borders can be seen. It measures 70 mm (longitudinal) (on 17/12/08 80 mm) × 40 mm [...] It has a solid and non-uniform structure due to the presence of countless isolated groups of microcalcification echo reflections. Color-doppler, hindered by the movements of the child, showed some intralesional vessels with a low resistance index. Nothing of note regarding the kidneys or the organs in the upper abdomen [...] ".
The treatment was revised by Prof. Luigi Di Bella on 12/Mar/1999, altering the daily dose of Somatostatin from 0.25 mg/day to 0.5 mg on alternate days for 3 times a week, continuing with 0.25 mg on the other 4 days of the week, and leaving the rest of the treatment unchanged.
Six months after starting the therapy, an MRI on 18/Jun/1999 showed a regression of the tumour of around 50%.
18/Jun/1999: MRI – Report: " [...] The procedure was carried out with the turbo-spin-echo technique, along the axial and coronal planes, with inversion-recovery sequences and T2-weighted scans, after i.v. injection of gadolinium. Compared with the previous scan on 24/12/98, there is a notable reduction of the retroperitoneal tumour in the left para-aortic and paravertebral region, now measuring 5 cm in length and 2 cm in width. The liver, spleen, pancreas, kidneys and adrenal glands are not affected." (Figure 6, Figure 7, Figure 8, Figure 9 and, together, Figure 6-7, Figure 8-9 and Figure 6-7-8-9).
At the same time, the values of ESR, LDH, Ferritin, NSE, urinary excretion of Vanillylmandelic acid, Homovanillic acid and Catecholamines had returned to within the normal physiological range.
After one year of treatment, an MRI, carried out on 21/01/2000 in Catania, showed the almost total disappearance of the Neuroblastoma.
21/Jan/2000: MRI – Report: " [...] The MRI was carried out with the spin-echo technique, along the axial and coronal planes, with inversion recovery sequences and T2-weighted scans, after i.v. injection of gadolinium. Compared with the previous scan on 18/06/99, the retroperitoneal neoformation previously visible in the left para-aortic and paravertebral region has almost totally disappeared, now represented by a small residue in the para-aortic region. The other findings are as before." (Figure 10, Figure 11, Figure 12, Figure 13 and, together, Figure 10-11, Figure 12-13 and Figure 10-11-12-13).
In September 2000 (child’s age: 28 months) Prof. Luigi Di Bella revised the treatment as follows:
-
Solution of:
- All-trans retinoic acid 0.5 g
- Palmitate axerophthol 0.5 g
- Beta carotene 2 g
- Alpha-tocopherol 1000 g
One 2.5 ml teaspoonful of Solution three times a day, morning – mid-day – evening (at least 15 minutes before meals) together with:
- Dihydrotachysterol: 4 drops in the teaspoon for each administration;
-
Bromocriptine 2.5 mg tablets: 1/2 of a tablet twice a day;
-
Melatonin 12%, Adenosine 51%, Glycine 37%: 2 mg tablets – 2 tablets in the morning and at mid-day, 4 tablets before bed;
-
Somatostatin – 14 amino acids: one 0.75 mg vial injected slowly subcutaneously in the evening.
From 2001 the dose of Somatostatin was increased to 1 mg every evening, leaving the rest unchanged.
In March 2001 an MRI with contrast medium showed " [...] the total absence of tumoral traces.".
The treatment was further reduced by completely eliminating Cyclophosphamide, Bromocriptine, Chondroitin sulfate, and Calcium. The dose of Somatostatin was reduced to 1 mg subcutaneously on alternate days 3 times a week. From 2002 the administration of Somatostatin was limited to 1 mg a week, from 2003 1 mg every 15 days, and then completely discontinued in 2007, while at the time of writing the administration continues of retinoids with 8 drops of Vit.D3 (Dihydrotachysterol) every morning before eating, and four 2 mg tablets of MLT after the evening meal.
Since 2001 all the subsequent blood tests and imaging procedures (PET, MRI) have confirmed the absence of disease with complete remission of the NBL.
07/Oct/2003: PET – Report: "Absence of areas of pathological accumulation of the metabolic trace agent [...] . The PET scan does not show any alterations that can be attributed to the presence of surrogate disease with high metabolic activity".
20/Sep/2004: PET – Report: "No evidence of pathological accumulation of the metabolic trace agent [...] . The PET scan does not show any alterations that can be attributed to the presence of surrogate disease with high metabolic activity".
06/Oct/2005: MRI – Report: " [...] Complete macroscopic regression of the expansive tumoral lesion localised in the abdominal-pelvic retroperitoneal area and incorporating the left iliac vessels [...] ".
17/Mar/2008: PET – Report: "Today’s follow-up PET scan, compared with the previous scans in 2003 and 2004, does not show any evidence of pathological accumulation of the metabolic trace agent in the explored area. In particular, nothing to report in the abdomen [...] " (Figure 14).
DISCUSSION
The biological neuro-immuno-endocrine therapy prescribed by Prof. Luigi Di Bella (DBM) achieved a complete objective response in fourteen months, with no toxicity. by means of a receptorial, differentiating, apoptotic and antiproliferative mechanism of action, with criteria, methods and mechanisms of action totally different to the usual cytotoxic and cytolytic treatments, proving that it can replace surgery, and radiotherapy and/or chemotherapy which are in any case unable to provide results that are comparable to surgery but which may precede or follow it.
Rationale of the Therapy
The ubiquitary receptorial expression of Prolactin and GH (De Souza et al. 1974; Hooghe et al. 1998; Tada et al. 1999; Ben-Jonathan et al. 2002) represents one of the aspects of the direct and generalised mitogenic role of these molecules. The use of SST and/or Octreotide in all tumoral diseases is widely justified by the negative regulation of GH, a hormone with a high mitogenic potential, GH-correlated mitogenic growth factors and neoplastic angiogenesis. This justifies the use of somatostatin and its analogs in all tumors (Di Bella et al. 1979; Manni et al. 1989; Klijn et al. 1996; Pollak et al. 1997; Pawlikowski et al. 1998; Lachowicz-Ochedalska et al. 2000; Friend et al. 2000; Schally et al. 2001; Schally et al. 2003; Massa et al. 2004; Arena et al. 2007; Guillermet-Guibert et al. 2007; Lee et al. 2008) with particular efficacy in neuroendocrine tumours such as NBL, characterised by a high receptorial expression for somatostatin (Moertel et al. 1994; Sestini et al. 1996; Kogner et al. 1997; Briganti et al. 1997; Borgström, 1999; Friend et al. 2000; Steták et al. 2001; Orlando et al. 2001; Florio et al. 2008). SSTRs have also been identified in a wide range of non-neuroendocrine tumours (Schaer et al. 1997; Van Eijck et al. 1998; Held-Feindt et al. 1999; Mishima et al. 1999; Pinzani et al. 2001; Watson et al. 2001; Barnett et al. 2003). A causal relationship has been demonstrated between GH (of which SST is the biological antidote) and tumoral induction and progression (Zeitler et al. 2000), by histochemically detecting markedly higher concentrations of GHR in tumoral tissue with respect to healthy tissue. The powerful mitogenic role of GH, with a proliferative index and speed of progression of the neoplastic population directly proportional to the receptorial expression of GH, is therefore known and documented H (Lincoln et al. 1998). The loss of differentiation and the uncontrolled proliferation, albeit to different extents, are common denominators of all tumours. Through a differentiating and antiproliferative factorial synergic mechanism, the other components of the DBM reinforce the antitumoral activity of SST.
Interaction of the MDB with the cytogenic and molecular aspects of NBL
In NBL the loss of heterozygotes 1 P (1P LOH) is associated with amplification of the oncogene N- MIC, which is not ascertained in only 3% of cases. The inhibition of various oncogenes, including MIC by some of the components of the DBM, has been documented (Degli Uberti et al. 1991; Peverali et al. 1996; Sun et al. 2002; Gumireddy et al. 2003; Durand et al. 2008; Aktas et al. 2009). The chromosome damage of NBL leads to varying degrees of inactivation of oncosuppresor genes: CD 44, Bcl-2, P53, as well as Caspase 3–8, key elements of the apoptotic cascade. Oncosuppressor inactivation occurs simultaneously with the amplification of oncogenes such as the N-myc gene and the proto oncogene TRK, considered one of the cytogenetic causes of neuroblastoma. The negative regulation of the oncosuppressors is also antagonised by the components of the DBM, such as retinoic acid which inhibits the inactivation of caspase (Piedrafita et al. 1997; Takada et al. 2001; Jiang et al. 2008) and MLT which protects P53 and Bcl-2 from degradation (Mediavilla et al. 1999). One of the pathogenetic factors of NBL is the altered response of the neuroblasts to the differentiating stimulation, effectively countered by the retinoids which induce neuronal differentiation (Hassan et al. 1990; Giannini et al. 1997; Peverali et al. 1998; Voigt et al. 2000, Ueda et al. 2001; Kulikov et al. 2007; Beijersbergen et al. 2009; Wu et al. 2009; Witzigmann et al. 2008). The differentiation is synergically reinforced by other components of the DBM, such as Melatonin (Cos et al. 1996; Garcia-Santos et al. 2006; McMillan et al. 2007), Vitamin D3 (Lange et al. 2007), Vitamin E (Turley et al. 1995; Swettenham et al. 2005), Vitamin C (Carosio et al. 2007) and Chondroitin sulfate (Batra et al., 1997; Pumphrey et al. 2002).
In NBL there is an alteration of the NGF-TRK receptor-ligand system, consisting of the interaction between families of transmembrane receptors and tyrosine-kinase A-B-C activity, and ligands consisting of trophism and central and peripheral nervous growth systems, represented by nerve growth factor (NGF), neurotrophines (NT3-4-5), and Brain Derived Neurotrophic Factor (BDNF). Components of the MDB such as STT and retinoids (Giannini et al. 1997; Witzigmann et al. 2008; Liang et al. 2009) antagonise the proliferative stimulus of these molecules. The binding of NGF, NT and BDNF to TRK receptors induces the transactivation and phosphorylation of tyrosine residues with the start of a cascade of intracellular events aimed at cellular proliferation. The neuroblastoma cells contain various levels of expression of tyrosine kinase receptors. The Protein-Tyrosine kinase activity is effectively inhibited by SST and its analogs (Reardon et al. 1996; Pawlikowski et al. 1998; Lachowicz-Ochedalska et al. 2000; Cattaneo et al. 2000; Florio et al. 2001; Massa et al. 2004; Lee et al. 2008; Florio et al. 2007). The molecular equivalent of the clinical-prognostic aspects is regulated in the most aggressive NBLs by the reduced or non-expression of TRK –A, the increased expression of TRK-B and amplification of N- Myc negatively regulated by SST (Degli Uberti et al. 1991; Sun 2002 et al.; Durand et al. 2008 ). In NBLs with the worst prognosis there is little or no expression of CD44 and TRK-A, present due to MRP, together with high telomerasic activity. On the contrary, the decrease of TRK-B and N- Myc, together with the increased expression of TRK-A, is connected with a favourable prognosis, as is a high expression of somatostatin receptors (always present in NBLs).
Antiblastic molecular mechanisms of action of MDB
Cellular proliferation is strictly dependent on prolactin, GH, the main growth factor, and on GH-dependent mitogenic molecules, positively regulated by GH, such as EGF, FGF, HGF, IGF1-2, NGF, PDGF, VEGF and TGF, as well as by growth factors produced by the digestive tract, such as Gastrin, VIP, and CCK, also negatively regulated by SST (Kath et al. 2000). Both physiological and neoplastic cellular proliferation are triggered by these molecules, which are used to a much greater extent by the tumour cells than by healthy cells. Biolog ical antidotes of GH, Somatostatin and its analogs, do not merely reduce the expression and transcription of highly mitogenic growth factors, such as IGF1-2 (Sall et al. 2004), EGF (Szepesházi et al. 1999) and FGF (Held-Feindt et al., 1999), but extend their negative regulation to the respective receptors with evident antiproliferative (Mishima et al. 1999) and antiangiogenic effects (Barrie et al. 1993; Albini et al. 1999; Vidal et al. 2000; Watson et al. 2001;. Bocci et al. 2007).
It is known that the GH-IGF1 axis has a determining influence on neoplastic biological development (Murray et al. 2004). The IGFRs respond mitogenically to IGF. The suppressive effect of SST and its analogs on serum levels of IGF1 is both direct, through inhibition of the IGF gene, and indirect, through the suppression of GH and thus of its hepatic induction of IGF1 (Sall et al. 2004).
It has been widely documented that neoplastic progression is strictly dependent on angiogenesis which represents an obligatory and essential phase. Somatostatin and its analogs negatively regulate all stages of angiogenesis, such as the cascade of monocytes (Wiedermann et al. 1993), Interleukin 8, Prostaglandin E 2, and endothelial Nitric oxide synthase (e-Nos) (Florio et al. 2003), as well as growth factors whose synergy is essential for angiogenesis, such as VEGF (Cascinu et al. 2001; Mentlein et al. 2001) TGF, IGF1 (Murray et al. 2004; Hagemeister et al. 2008) FGF, HGF (Jia et al., 2003; Hagemeister et al. 2008), PDGF (Cattaneo et al. 1999), and EGF (Mishima et al. 1999; Szepesházi et al. 1999; Held-Feindt et al., 1999). The inhibition of angiogenesis induced by Somatostatin (SST) is synergically and factorially reinforced by the other components of the MDB such as Melatonin (Di Bella et al. 2006; Lissoni et al. 2001), Retinoids (Majewski et al. 1994; McMillan K. et al. 1999; Kini et al. 2001), Vitamin D3 (Kisker et al. 2003; Mantell et al. 2000), Vitamin E (Shklar et al. 1996; Tang et al. 2001), Vitamin C (Ashino et al. 2003), prolactin inhibitors (Turner et al. 2000) and components of the extracellular matrix (Ozerdem et al. 2004; Liu et al. 2005).
In a similar way, the cytostatic, antiproliferative and antimetastatic effect of Somatostatin (Kogner et al. 1997; Orlando et al. 2001; Arena et al. 2006; Guillermet-Guibert et al. 2007; Barbieri et al. 2008) is effectively synergised by the other components of the MDB, such as Retinoids (Hassan et al. 1990; Onogi et al. 1998; Piedrafita et al. 1997; Voigt et al. 2000; Witzigmann et al. 2008), Melatonin (Kvetnoĭ et al. 1986; Maestroni et al. 1996; Cos et al. 2000; Bartsch et al. 1999; Mediavilla et al. 1999; García-Santos, et al. 2006; Pizarro et al., 2008), Vitamin D3 (Celli et al. 1999; Barroga et al. 2000; Campbell et al. 2000; Jensen et al. 2001; Stio et al. 2001), the prolactin inhibitors Cabergoline and Bromocriptine (Manni et al., 1989; Klijn et al. 1996; Gruszka et al. 2001), Galactosamine sulfate, components of the extracellular matrix (Batra et al. 1997; Pumphrey et al. 2002), Vitamin E (Turley et al. 1995; Shklar et al., 1996; Israel et al. 2000; Malafa et al. 2002; Neuzil et al. 2002) and Vitamin C (Cameron et al. 1979; Murata et al. 1982; Head et al. 1998; Carosio et al. 2007). The literature has therefore confirmed the synergic antineoplastic, differentiating, antiproliferative, antiangiogenetic and antimetastatic mechanisms of action of all the components of the DBM.
The objective result, with no toxicity, of the rapid reduction and disappearance of a retroperitoneal mass measuring 4×8 cm in a seven-month-old child, together with the blocking of all metastatic dissemination, demonstrates the efficacy of this treatment and is in agreement with the positive results achieved with the use of the MDB in lymphoproliferative diseases (Todisco et al. 2001; Todisco et al. 2006; Todisco et al. 2009), stage 3 and 4 lung cancer (Norsa et al. 2006; Norsa et al. 2007), breast cancer (Di Bella et al. 2009). Without the need for hospitalisation or even day hospital, and without in any way impairing the psychophysical development of the child, the MDB avoided difficult radical surgery, which also involved a high risk since the distal aorta and vena cava, the bifurcation and the iliac arteries and veins were incorporated and displaced by the tumoral mass. It also made it possible to avoid chemo- and radiotherapy with their known and serious contraindications.
The blood tests and the diagnostic procedures showed a progressive decrease in the volume of the tumour, together with a reduction of the amine metabolites of the adrenergic system that are typical of neuroblastoma, such as catecholamine, Vanillylmandelic acid and Homovanillic acid, together with neuroendocrine markers such as NSE, and molecules like Ferritin and HDL which are typical of this disease. The complete objective result in little more than a year, together with the blocking of all metastatic dissemination, frequent in NBL, shows the efficacy of this treatment. The continuous administration of the components of the MDB for over 10 years was perfectly tolerated, allowing immunitary and neuroendocrine homeostasis well within physiological limits, and excellent psychophysical development.
The early application of the MDB as a first line therapy in a patient who was not weakened by the toxic, mutagenic and immunodepressive effects of chemo-radiotherapy was of considerable help to the result. We believe it is of use to report this case to invite greater interest and more detailed research into the possibilities offered in the oncological field by the immunoneuroendocrine, biological and receptorial treatment of the DBM.
Complete objective response of neuroblastoma to biological treatment
[1] Brodeur GM, Pritchard J, Berthold F, et al. - Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11 (8): 1466-77, 1993;
[2] Brodeur GM, Seeger RC, Barrett A, et al. - International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6 (12): 1874-81, 1988;
[3] Ikeda H, Iehara T, Tsuchida Y, et al. - Experience with International Neuroblastoma Staging System and Pathology Classification. Br J Cancer 86 (7): 1110-6, 2002;
[4] Taggart DR, London WB, Schmidt ML, et al. - Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol 29 (33): 4358-64, 2011.